WM
Witter Malcolm G Director
Board M
US US · SEC (Form 4)
€97,447
▲ Purchases (4 ops.)
Explore the complete record of transactions filed by Witter Malcolm G, Director. Insider active across 1 companies, notably Navidea Biopharmaceuticals, INC.. In total, 18 disclosures have been logged. Total volume traded: €97k. The latest transaction was disclosed on 31 May 2022 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations 18 total
02,500 shares 0
Common Stock
SEC:0001437749-22-014047:0 · 31 May 2022
02,500 shares 0
Common Stock
SEC:0001437749-22-010728:0 · 30 Apr 2022
02,500 shares 0
Common Stock
SEC:0001437749-22-007863:0 · 31 Mar 2022
02,500 shares 0
Common Stock
SEC:0001437749-22-004853:0 · 28 Feb 2022
02,500 shares 0
Common Stock
SEC:0001437749-22-002113:0 · 31 Jan 2022
02,500 shares 0
Common Stock
SEC:0001437749-22-002113 · 31 Jan 2022
02,500 shares 0
Common Stock
SEC:0001437749-22-000326 · 31 Dec 2021
02,500 shares 0
Common Stock
SEC:0001437749-22-000326:0 · 31 Dec 2021
€26 30,000 shares @ €0.0009 0.1% of flow
Common Stock
SEC:0001437749-21-027701 · 15 Nov 2021
€26 30,000 shares @ €0.0009 0.0% of flow
Common Stock
SEC:0001437749-21-027701:0 · 15 Nov 2021
03,995 shares 0
Common Stock
SEC:0001437749-21-023085 · 30 Sept 2021
03,995 shares 0
Common Stock
SEC:0001437749-21-023085:0 · 30 Sept 2021
€27,153 20,000 shares @ €1.3576 55.7% of flow
Common Stock
SEC:0001437749-21-022353 · 17 Sept 2021
Ideal exit: 14 Jun 2022 (T+270) €27,153 20,000 shares @ €1.3576 27.8% of flow
Common Stock
SEC:0001437749-21-022353:0 · 17 Sept 2021
Ideal exit: 14 Jun 2022 (T+270) €21,571 15,000 shares @ €1.438 44.2% of flow
Common Stock
SEC:0001437749-21-017568 · 26 Jul 2021
Ideal exit: 22 Apr 2022 (T+270) €21,571 15,000 shares @ €1.438 22.1% of flow
Common Stock
SEC:0001437749-21-017568:0 · 26 Jul 2021
Ideal exit: 22 Apr 2022 (T+270) 03,757 shares 0
Common Stock
SEC:0001437749-21-016600 · 30 Jun 2021
03,757 shares 0
Common Stock
SEC:0001437749-21-016600:0 · 30 Jun 2021
About Witter Malcolm G Malcolm G Witter is an executive at NAVIDEA BIOPHARMACEUTICALS, INC.